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sheds new light on cellular control via tail
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As the phosphoinositol-3-kinase antagonist in the
PI3K pathway, the PTEN tumor suppressor exerts
phosphatase activity on diacylphosphatidylinositol
triphosphate in the plasma membrane. Even partial
loss of this activity enhances tumorigenesis, but a
mechanistic basis for this aspect of PTEN physiology
has not yet been established. It was recently pro-
posed that PTEN mutations have dominant-negative
effects in cancer via PTEN dimers. We show that
PTEN forms homodimers in vitro, and determine a
structural model of the complex from SAXS and
Rosetta docking studies. Our findings shed new light
on the cellular control mechanism of PTEN activity.
Phosphorylation of the unstructured C-terminal tail
of PTEN reduces PTEN activity, and this result was
interpreted as a blockage of the PTEN membrane
binding interface through this tail. The results pre-
sented here instead suggest that the C-terminal tail
functions in stabilizing the homodimer, and that tail
phosphorylation interferes with this stabilization.
INTRODUCTION
The diacylphosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P3)-
specific lipid phosphatase PTEN (Li et al., 1997; Steck et al.,
1997) is frequently mutated in human cancers (Simpson and Par-
sons, 2001; Stiles, 2009) and suppresses cell proliferation by
limiting AKT phosphorylation in the phosphoinositide-3-kinase
(PI3K) signaling pathway. Even partial loss of PTEN activity (hap-
loinsufficiency) enhances tumorigenesis (Berger et al., 2011).
Genetic loss of Pten and mutations that affect functionality of
the expressed protein are not equivalent, as patients with
missense mutations develop lesions at a higher frequency than1952 Structure 23, 1952–1957, October 6, 2015 ª2015 Elsevier Ltd Apatients with gene deletion or drastic truncations (Marsh et al.,
1998), so that missense mutations are, paradoxically, worse
than nothing (Leslie and den Hertog, 2014). These observations
can be rationalized by postulating that PTEN dimerizes in its
active form, and indeed a recent study presented evidence for
PTEN dimerization in vivo and inferred that dimers are more
active phosphatases than monomers (Papa et al., 2014). Here,
we study structural aspects of PTEN dimerization in vitro. We
find that the dimer state of bacterially expressed PTEN is favored
over the monomeric form, and derive a structural model of the
PTEN dimer complex from small-angle X-ray scattering (SAXS)
and docking studies that is consistent with earlier neutron reflec-
tion (NR) and molecular dynamics (MD) results (Shenoy et al.,
2012a). The PTEN monomer includes multiple disordered seg-
ments, the largest of which is its C-terminal tail (Lee et al.,
1999). While the monomer is partially unstructured as shown
by the SAXS results, the dimer is well folded and forms a
compact particle, suggesting that the C-terminal tail plays a
role in dimer stabilization. Phosphorylation of the tail was shown
to inhibit PTEN membrane phosphatase activity (Rahdar et al.,
2009). In addition, it affects the efficiency of dimerization (Papa
et al., 2014). In combination with our structural results reported
here, this suggests a novel control mechanism in which phos-
phorylation weakens the association of the two C-terminal tails
with the protein domains, thereby destabilizing the dimer, while
dimerization is presumably required for the phosphatase to
reach its full enzymatic activity.
PTEN is a 403-amino-acid (aa) protein with an N-terminal,
dual-specificity phosphatase domain and a C-terminal, non-
canonical C2 domain that binds anionic lipids independent
of Ca2+ (Lee et al., 1999). In addition, PTEN includes a short
(13 aa) N terminus and the 51-aa C terminus, both of which are
unstructured. While the tumor suppressor function of PTEN
depends on the interaction of the phosphatase with the plasma
membrane (PM), the vast majority of the protein resides in the
cytosol and interacts with the PM only sporadically (Redfern
et al., 2010; Vazquez et al., 2006). Cellular control of this dy-
namic interaction has been debated (Ross and Gericke, 2009);ll rights reserved
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Figure 1. SAXS Measurements and Data Analysis
For a biochemical characterization of PTEN dimer formation, see Figure S1.
(A) Protein concentration determined by UV absorbance (blue) and by the
X-ray scattering intensity of a sample of PTEN eluted from an SEC. Molecular
weight markers were derived from a calibration run with standards from Bio-
Rad between 1.35 kDa (vitamin B12) and 670 kDa (thyroglobulin). The inte-
grated X-ray scattering intensity on the detector is shown in red; black data
points show I0, the background-corrected radial averages of the forward
scattered X-ray intensities extrapolated to q = 0. I0 values are only shown for
exposures that were further used for data analysis, close to the maximum of
the monomer elution peak atz14.1 ml. Because the exact length of az1-min
delay between passage of the protein solution through the UV detector and the
X-ray beam is not precisely known, signals were horizontally shifted to coin-
cide at the peak positions. The time lag resulting from the travel of the sample
in the capillary results in a broadening of the protein concentration-dependent
X-ray intensities in comparison with the concentration-dependent UV absor-
bance. The difference between integrated X-ray intensity and I0 at elution
volumes >14.5 ml is likely due to protein adsorption on the cuvette walls. The
inset shows the reduced SAXS data associated with these 14 exposures.
(B) Pair distribution functions of the scattering centers derived from the
scattering curves in the inset in (A) show a systematic dependence of their
maximum positions on protein concentration in the beam (proportional to their
integrated areas). As a guide for the eye, the dashed line indicates these
maxima of P(R).
(C) Normalized SAXS intensities (thin lines) and their decomposition into
two basis vectors from a simultaneous fit to all 14 datasets. The component
Structure 23, 1952–in particular, phosphorylation of the C-terminal tail affects
PTEN membrane localization (Rahdar et al., 2009). While other
post-translational modifiers may affect PTENmembrane binding
(Huang et al., 2012), we showed that bacterially expressed PTEN
binds lipid membranes in vitro with high affinity and a strong
dependence on lipid composition (Shenoy et al., 2012b).
RESULTS
As a test for PTEN homodimerization in vitro, a glutathione
S-transferase (GST) pull-down assay with purified GST-PTEN
and PTEN-His6 on a glutathione column showedHis-tagged pro-
tein after elution. This signal was confirmed by western blotting
using a His-tag specific antibody (Figure S1). Next, we used
SAXS to characterize the structure of bacterially expressed
PTEN. In distinction from the protein used in the pull-down
assay, this PTEN was tag-free. The protein was eluted from a
size-exclusion chromatography (SEC) column and tracked by
UV absorbance (Figure 1A). This trace is overlaid with the total
X-ray scattering intensity, collected in >250 individual exposures
of the eluted protein as it passes through the X-ray beam,
approximately 1 min after passing the UV detector. In addition,
the extrapolated (q / 0), background-corrected X-ray inten-
sities, I0, are shown for 14 exposures across the elution peak.
We selected 14 SAXS exposures of protein from the major
elution peak, indicated by their I0 values in Figure 1A and shown
in the inset, for a detailed evaluation. While we expected to
observe scattering from a homogeneous PTEN fraction, a
detailed analysis raised doubts about this interpretation. The
maxima of the pair distribution functions, P(R), shifted to higher
R valueswith increasing I0 (proportional to the protein concentra-
tion in the beam), as shown in Figure 1B. Similarly, we noticed
differences in the slopes of the Guinier plots, i.e., the radii of gy-
ration of the scattering particles (Figure S2). While small, these
differences showed a systematic dependence on protein con-
centration. In view of these concentration-dependent variations,
we decomposed the 14 SAXS exposures into linear combina-
tions of two basis vectors and found that this two-state model
fitted all experimental data simultaneously within experimental
errors. The basis vectors (colored lines in Figure 1C) and their
weights in each SAXS curve correspond to the scattering of
two distinct species and their relative concentrations in each
exposure. These relative concentrations depend systematically
on total protein concentration in the sample (inset in Figure 1C).
Figure 1D shows the corresponding P(R) profiles. The two PTEN
species identified in the decomposition have radii of gyrations,
Rg = 2.49 and 2.93 nm. Their Porod volumes were VP = 55 ±
10 and 98 ± 2 nm3, suggesting that the particle with the lower
Rg is a PTEN monomer and that with the larger Rg is a homo-
dimer. The same conclusion was derived from a more elaboratecoefficients that represent the fraction of protein in the dimer are shown in
the inset.
(D) Pair distribution functions corresponding to the basis vector scattering
curves in (C).
(E) Normalized Kratky plots of the two basis vectors in (D) for the monomer and
the dimer. Dashed lines are guides to the eye.
Error bars in (C) and (D) indicate 68% confidence intervals. For Guinier plots of
the SAXS data, see Figure S2.
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Figure 2. Structural Modeling the Decomposed SAXS Results
(A) Reconstructed envelope of scattering density for the PTEN monomer in
solution with a ribbon model of the truncated crystal structure (Lee et al., 1999)
superimposed.When docked to themembrane, the direction of themembrane
normal coincides with the green arrow. Two orthogonal rotations transform the
view shown in the center into the views to the right and the left.
(B) Rosetta score versus Rg for trial configurations from global and local
Rosetta runs that yielded a Rosetta energy score of602 or less, and a radius
of gyration 26.6% Rg% 32.6 A˚. The symbol color encodes the fit quality (c
2)
between the SAXS curves calculated from the configurations and the experi-
mental SAXS curve obtained for the putative dimer from the decomposition.
Because the error bars are slightly overestimated by the data reduction
software provided by the facility, the best models show c2 values below unity.
The symbol size represents the interfacial energy score Isc from Rosetta. All
symbols larger than the minimum size have interfacial energies that are
considered ‘‘good’’ with values 5 % Isc % 10. The score funnel at Rg = 29 A˚
yields the globally lowest Rosetta scores and the best fit to the data.
(C) Graphical representation of configurations with the lowest Rosetta scores
for the four score funnels indicated in (B).
(D) Reconstructed envelope of scattering density for the large particle obtained
from the decomposition, as in (A). The PTEN dimer corresponding to config-
uration 3 in (B) is superimposed as a ribbon structure.analysis of the masses of the scattering particles based on
scaling relations (Rambo and Tainer, 2013; Watson and Curtis,
2014), as shown in detail in Figure S3 and Table S1. Normalized
Kratky plots for the monomer and dimer differ significantly at
high values of (q3 Rg) (see Figure 1E). Whereas the dimer nearly
returns to zero baseline, the monomer does not show conver-1954 Structure 23, 1952–1957, October 6, 2015 ª2015 Elsevier Ltd Agence. In line with current interpretation of SAXS protein signa-
tures (Rambo and Tainer, 2011), we conclude that the monomer
is partially disordered while the dimer is well folded in its entirety,
including the C-terminal tails.
GASBOR (Svergun et al., 2001) was used for a protein shape
reconstruction based on the monomer and dimer vectors. For
the monomer, the corresponding envelope was found to fit the
PTEN crystal structure well (Figure 2A). This structure was deter-
mined for a truncated protein that lacks z18% of the mass of
full-length PTEN (Lee et al., 1999), and the visible underfilling
of the protein volume defined by the SAXS results is therefore
expected. This approach to data modeling appears reason-
able, as all-atom MD simulations of PTEN suggested that there
are only subtle differences between the crystal structure of the
folded PTEN domains and its solution structure (Shenoy et al.,
2012a). As expected from the dimer vector, the envelope
computed for the PTEN dimer showed about twice the volume
of the monomer envelope. Due to the lack of atomic-scale struc-
tural information on the unstructured protein segments, our
search for trial dimer structures using Rosetta (Lyskov et al.,
2013) was performed with the truncated crystal structure (Lee
et al., 1999). Independent runs with and without constraints to
C2 symmetry yielded similar low-energy results. Eventually, an
unconstrained local run yielded the structure funnel that led to
the result with the overall lowest energy score. By sorting the
entire set of Rosetta results (z105 trial structures) according to
theirRg values (Figure 2B), four clusters were identified. The con-
figurations associated with all four score funnels are structurally
related in that dimerization is driven by interactions between the
phosphatase domains while they differ by a translational
offset along the protein binding interface (Figure 2C). In addition,
the membrane binding interfaces of both monomers face in the
same direction in all these models. However, among these clus-
ters there is only one that fits the experimental data well and is
compatible with the Rg value,z2.9 nm, determined for the de-
composed pair distribution function vector. The configurations
with the lowest Rosetta energy score within this funnel are
almost identical in their structure and filled the dimer envelope
particularly well, as shown in Figure 2D for the hit with the overall
lowest energy score.
DISCUSSION
Although the formation of PTEN homodimers is well supported
by genetic evidence (Papa et al., 2014) and provides an intriguing
hypothesis relevant to cancer formation following mutation of a
single PTEN allele (Berger et al., 2011), the structure and function
of such dimers are poorly understood. Using pull-down experi-
ments, we detected dimer formation in bacterially expressed
PTEN. With tag-free PTEN protein, this result was verified by
SAXS on selected SEC eluent fractions in which we identified
PTEN monomer and dimer as a function of protein concen-
tration. By decomposition of the SAXS data into independent
contributions, we determined electron density envelopes of
two distinct particles that fit the crystal structure of a truncated
PTEN (Lee et al., 1999) monomer and dimer well. Supported
by Rosetta docking simulations, this suggests a candidate
structure for the PTEN homodimer. In recent MD simulations of
PTEN monomers in solution, we observed that the regulatoryll rights reserved
C-terminal tail shows some flexibility and associates with the
surface of the PTEN domains in multiple, similar conformations
(Shenoy et al., 2012a). While SAXS cannot locate the tail in the
candidate dimer structure, it shows conclusively that PTEN has
a more compact conformation in the dimer than the monomer
configuration, suggesting that the tail is stably associated with
the protein domain surfaces. If this association occurs across
the dimer, analogous to three-dimensional domain swapping
common for other proteins (Liu and Eisenberg, 2002; Rousseau
et al., 2003), this can provide a novel mechanism to stabilize the
PTEN homodimer.
While SAXS provides only low-resolution structural infor-
mation, our refinement of the scattering results with Rosetta
leads to an attractive model that shows features consistent
with previous biochemical characterizations of the PTEN dimer
(Papa et al., 2014). Furthermore, the importance of the C-termi-
nal tail for dimerization explains why the truncated PTEN protein
used for X-ray crystallography did not show a dimer (Lee et al.,
1999). This model also motivates predictions that can be tested
in future work. (1) Without imposing constraints, all low-energy
Rosetta models show approximate C2 symmetry and arrange
the monomers such that their membrane binding interfaces are
coplanar. This is consistent with the fact that no higher-order
oligomers are experimentally observed, and suggests that the
membrane affinity of the dimer is considerably higher than that
of themonomer. (2) In our structural model, the two phosphatase
domains form the dimer interface, whereas the C2 domains are
not involved in this interaction. This agrees with results by
Papa and co-workers, which showed that an N-terminal frag-
ment of PTEN that contained the phosphatase domain was
more effective in binding to full-length PTEN in a pull-down assay
than the C-terminal portion of the protein (Figure 2B in Papa
et al., 2014), suggesting that the phosphatase domain is indeed
critical for dimerization. While the two C2 domains thus act inde-
pendently of each other in membrane binding, the phosphatase
domains might mutually affect each other in the tightly bound
dimer state to optimize the efficiency of their catalytic sites.
(3) Rosetta predicts that major contacts within the dimer occur
between the two phosphatase domains, and implicates the
pa2 helix and pb4 sheet in dimer stabilization. These predictions
can be directly tested in futuremutation studies aimed at control-
ling the monomer-dimer equilibrium. (4) Finally, we suggest that
the C-terminal tails stabilize the dimer by crossing between
its monomeric constituents in a domain-swapping exchange. If
this is confirmed, it will be interesting to test whether inhibition
of the PTEN tumor suppressor function in cancer-associated
mutations results from a reduction of dimer stability, protein mis-
folding, or both. In our model, we speculate that cellular control
of PTEN activity results from dimer destabilization upon phos-
phorylation of the C-terminal tail. This hypothesis is consistent
with previous results by Papa and co-workers. These investiga-
tors showed that PTEN with a non-phosphorylatable version of
the C-terminal tail (PTEN4A), which is functionally more active
than wild-type PTEN (Vazquez et al., 2000), has increased
dimeric fractions in gel filtration assays (Figure 2I in Papa et al.,
2014). Moreover, MD simulations of soluble PTEN monomer
(Shenoy et al., 2012a) suggest that the C-terminal tail has a
tendency to fold against the PTEN domains and is sufficiently
long to obstruct the membrane binding interface, which mayStructure 23, 1952–interfere with dephosphorylation of the membrane bound lipid
substrate.
The results of this study lead to significant refinements of our
understanding of the mechanism for PI(3,4,5)P3 dephosphoryla-
tion by PTEN and its cellular control. The evolution of the under-
lying models is schematically summarized in Figure 3, starting
with the hypothesis in Figure 3A that phosphorylation of the
C-terminal tail interferes with PM binding of the PTEN monomer
(Rahdar et al., 2009; Ross and Gericke, 2009). Biochemical
and genetic evidence recently implied a PTEN homodimer in
maintaining PI(4,5)P2/PI(3,4,5)P3 homeostasis in healthy cells,
as shown in Figure 3B (Leslie and den Hertog, 2014; Papa
et al., 2014). Here, we refine this model by providing a structural
basis to the PTEN dimer hypothesis (Figure 3D), based upon
experimental observations in vitro and computational modeling
using the truncated PTEN X-ray structure (Figure 3C). Consistent
with this model, it was recently shown that the binding of the
phosphoinositide diC6PI(4,5)P2 to the N-terminal sequence of
PTEN was associated with PTEN dimer formation in solution
(Wei et al., 2015). Thus, high concentrations of PI(4,5)P2 in lipid
rafts may further promote PTEN accumulation and dimerization
in vivo, in agreement our in vitro experiments carried out with
high PTEN concentrations. Of note, refolding of domain swap
dimers may occur as a function of protein concentration (Rous-
seau et al., 2004).
In conclusion, we show that the bacterially expressed PTEN
phosphatase dimerizes efficiently in vitro at micromolar concen-
trations, and provide a candidate structure of the homodimer
with critical interactions between the two phosphatase domains.
Dimer formation may thereby result in cooperativity in PTEN
membrane binding through the paired C2 domains, leading to
increased enzyme affinity for the PM. In addition, the presumed
tight binding of the juxtaposed phosphatase domains to each
other could lead to conformational changes around the cata-
lytic site that enhance the efficiency of lipid dephosphorylation.
Clearly, the conjectures derived from our results need to be
tested in mutation studies of the proposed dimer binding
interface and manipulations of the phosphorylation state of the
PTEN C-terminal tail.EXPERIMENTAL PROCEDURES
Protein Expression and GST Pull-Down Assay
PTEN protein was expressed and purified as described by Redfern et al.
(2008). Human PTEN with a C-terminal His-tag was expressed in Escherichia
coli BL21 (DE3). For the SAXS experiments, the His-tag was cleaved off using
enterokinase. The GST pull-down assay was carried out using a batchmethod
(see Results and Figure S1). Purified GST-PTEN and PTEN-His6 were mixed in
an equimolar ratio and allowed to incubate a bed of pre-equilibrated gluta-
thione Sepharose 4B (GE Healthcare Life Sciences) for 1 hr at 4C on a rocker.
As a negative control, GST protein and PTEN-His6 were mixed using the same
protocol. The resin was washed with buffers containing 0.5% Triton X-100,
0.1% Triton X-100, and finally detergent-free wash buffer. The remaining
protein was eluted using 10 mmol/l reduced glutathione in Tris at pH 8.0.
The eluted fractions were analyzed by SDS-PAGE. To confirm the presence
of PTEN-His6, a western blot was carried out using a His-tag specific antibody.
Small-Angle X-Ray Scattering
Bacterially expressed, tag-free PTEN protein dissolved in 10 mM HEPES,
250 mM NaCl, and 1 mM DTT (pH 7.4) was investigated in SAXS experiments
at room temperature. Measurements were carried out at the APS BioCAT1957, October 6, 2015 ª2015 Elsevier Ltd All rights reserved 1955
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Figure 3. Evolution of PTEN Membrane Interaction Models
The figure is redrawn after Figure 1 in Leslie and den Hertog (2014). The
enzymatically productive PTEN species in each model are marked with
asterisks.
(A) Cellular control of PTEN membrane interaction through phosphorylation
(red dots) of the unstructured C-terminal tail (Rahdar et al., 2009). In this model,
the phosphorylated tail blocks the membrane binding interface of wild-type
PTEN, interfering with its enzymatic processing of PI(3,4,5)P3 in the plasma
membrane (Ross and Gericke, 2009). Mutant PTEN (red filled) may interact
with the membrane but is enzymatically inactive.
(B) The PTEN dimer hypothesis (Papa et al., 2014) explains the dominant-
negative behavior of PTEN mutants. Independent of tail phosphorylation, only
homodimers of wild-type PTEN are enzymatically active while monomers or
dimers that involve mutant PTEN are inactive or reduced in their activity.
(C and D) Refinement of the dimer model through this work. The SAXS results
provide a structural basis for the PTEN dimer hypothesis and lead to a rein-
terpretation of the role of tail phosphorylation. The structural model, Figure 2D,
predicts that the PTEN homodimer is formed through interactions between the
two phosphatase domains, in agreement with results from the pull-down
assays conducted by Papa and co-workers. Furthermore, the two membrane
binding interfaces in the dimer are oriented in the same direction and form a
flat, partially hydrophobic plane with exposed cationic residues for association
with the plasma membrane (C). Within the outline of the folded protein domain
in this schematic view, yellow residues mark the two CBR3 loops, the catalytic
cores (C124 residues) are shown in red, and the location where the C-terminal
tails emerge from the folded domains (E352 residues) is shown in green. As
indicated by the Kratky analysis, the C-terminal tails are firmly bound against
the folded PTEN domains, which suggests that the tails form ‘‘brackets’’ that
stabilize the dimer. These observations lead to the following refinement of the
dimer model (D). Wild-type PTEN homodimer formation may be required to
activate the phosphatase through structural adjustments around the substrate
binding pocket, making the dimer more productive than the wild-type PTEN
monomer. Alternatively, the increased productivity of the PTEN dimer could
also result just from a higher affinity to the anionic inner plasmamembrane than
that of a wild-type PTEN monomer. However, this would not explain why the
wild-type/mutant PTEN heterodimer has a strongly reduced enzymatic activ-
ity. In distinction to the scenario in (A), phosphorylation of the PTEN C-terminal
tail may decrease the interaction of the tail with the folded PTEN domains,
thereby reducing the stability of the dimer.beamline (sector 18) of Argonne National Laboratory, as described earlier
(Mathew et al., 2004). The 12-keV X-ray beam (l = 1.03 A˚) was focused on a
1.5-mm quartz capillary sample cell. The scattering, in the momentum transfer
range, q = 0.0065–0.3 A˚1, was collected on a Mar165 CCD detector approxi-1956 Structure 23, 1952–1957, October 6, 2015 ª2015 Elsevier Ltd Amately 2.5 m downstream of the sample position. The protein solution was fed
into the X-ray beam after passing through a Superdex-200 10/300 GL gel SEC
column onto whichz500 ml were loaded at 4 mg/ml. A capillary fed the eluent
first throughaUVdetector and then to theSAXSsamplecell. Thedelaybetween
protein emerging from the SEC column and its arrival at the beam position
was about 1 min. SAXS exposures with a length of 1 s were collected every
5 s during the gel filtration chromatography run. Exposures before and after
sample elution were averaged and used as buffer background. Exposures dur-
ing elution that coincided with the UV peak on the chromatogram were treated
as sample (protein+ buffer) SAXScurves. Pair distribution functions,P(R), of the
scattering centers were computed from the scattering curves using GNOM
(Svergun, 1992). To analyze the systematic shift of scattering curves with sam-
ple concentration, we decomposed these into two basis functions by global
fitting of all 14 SAXS spectra simultaneously with a Monte Carlo Markov chain,
similar to a procedure previously described for the evaluation of NR data (Kirby
et al., 2012). Full details are provided in Figures S2 and S3, and Table S1.
Rosetta Protein Docking
Prior to the docking simulations, the truncated X-ray structure of the PTEN
monomer (Lee et al., 1999) was supplemented with hydrogen atoms using
MolProbity4 (Chen et al., 2010), and pre-packed using the Rosetta 3.5 Prepack
Protocol (Gray et al., 2003). Unconstrained global docking simulations using
the Rosetta 3 Protein Docking Protocol (Gray et al., 2003) were performed
using two copies of the pre-packed structure as input. The orientations of
both docking partners were randomized, and default options for adding extra
side-chain rotamers were applied (Wang et al., 2005). Local docking simula-
tions without symmetry constraint did not randomize the orientations of the
docking partners but, instead, allowed for a random perturbation of the input
structures using a Gaussian for translation and rotation with SDs of 8 A˚ and
8, respectively. The Rosetta 3.5 Symmetric Docking Protocol (Andre´ et al.,
2007) was used for the docking simulation with C2 symmetry constraint.
Default options for adding side-chain rotamers were applied. All docking
simulations were performed with the low- and the high-resolution part of the
protocol. ATSAS Crysol (Svergun et al., 1995) was used with default parame-
ters to calculate the radius of gyration for every configuration, and to fit the
theoretical SAXS curve to the experimental data. The option of a constant
subtraction was enabled during the fit.
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